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Matrix Metalloproteinases and Glaucoma Treatment
Robert N. Weinreb,1 Michael R. Robinson,2 Mohammed Dibas,2 and W. Daniel Stamer3
Abstract
Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade extracellular matrix (ECM)
components such as collagen and have important roles in multiple biological processes, including development and
tissue remodeling, both in health and disease. The activity of MMPs is influenced by the expression of MMPs and
tissue inhibitors of metalloproteinase (TIMPs). In the eye, MMP-mediated ECM turnover in the juxtacanalicular
region of the trabecular meshwork (TM) reduces outflow resistance in the conventional outflow pathway and helps
maintain intraocular pressure (IOP) homeostasis. An imbalance in the MMP/TIMP ratio may be involved in the
elevated IOP often associated with glaucoma. The prostaglandin analog/prostamide (PGA) class of topical ocular
hypotensive medications used in glaucoma treatment reduces IOP by increasing outflow through both conventional
and unconventional (uveoscleral) outflow pathways. Evidence from in vivo and in vitro studies using animal models
and anterior segment explant and cell cultures indicates that the mechanism of IOP lowering by PGAs involves
increased MMP expression in the TM and ciliary body, leading to tissue remodeling that enhances conventional and
unconventional outflow. PGA effects on MMP expression are dependent on the identity and concentration of the PGA.
An intracameral sustained-release PGA implant (Bimatoprost SR) in development for glaucoma treatment can reduce
IOP for many months after expected intraocular drug bioavailability. We hypothesize that the higher concentrations of
bimatoprost achieved in ocular outflow tissues with the implant produce greater MMP upregulation and more
extensive, sustained MMP-mediated target tissue remodeling, providing an extended duration of effect.
Keywords: bimatoprost, extracellular matrix, glaucoma, intraocular pressure, matrix metalloproteinase, pros-
taglandin analog
Introduction
Matrix metalloproteinases (MMPs) are present invirtually all areas of the eye and are responsible for the
maintenance and remodeling of ocular architecture by influ-
encing a wide range of processes such as basement membrane
remodeling, blood–retinal barrier integrity, wound healing,
debris clearance, neovascularization, and fibrotic repair tissue
deposition.1–3 MMPs are believed to have a role in the path-
ophysiology of many ocular diseases including dry eye dis-
ease, age-related macular degeneration, diabetic retinopathy,
and glaucoma (Table 1).4 This article reviews the role of
MMPs in glaucoma, the involvement of MMPs in the mech-
anism of intraocular pressure (IOP) lowering with topical
prostaglandin analog/prostamide (PGA) medications, and the
development of a PGA intracameral implant to elicit more
sustained MMP-mediated target tissue remodeling for an ex-
tended duration of effect.
Overview of the Role of MMPs
in Health and Disease
Tissues contain cells in a scaffold of extracellular matrix
(ECM) composed predominantly of a heterogeneous and
tissue-specific mix of fibrous proteins (predominantly colla-
gen), proteoglycans, and glycosaminoglycans.5 The ECM is
a highly dynamic structure that undergoes continuous re-
modeling to maintain cellular and tissue homeostasis.5 This
remodeling is largely mediated by a large family of zinc-
dependent proteolytic enzymes known as the MMPs, whose
substrates include ECM components (eg, collagen, fibro-
nectin), as well as secreted cytokines (eg, tumor necrosis
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factor-a, transforming growth factor-b) and cell adhesion
molecules (eg, e-cadherin).1
MMP-mediated degradation of the ECM has an impor-
tant role in growth and development, morphogenesis, and
tissue repair and remodeling (Fig. 1A). For instance, over
half of the members of the MMP family are involved in
promoting bone growth and development under normal
physiological conditions,6 and mutations in the human
MMP2 and MMP14 genes have been linked to rare skeletal
diseases characterized by loss of bone tissue and short
stature.7
MMPs are produced by a wide variety of cell types (eg,
stromal fibroblasts, macrophages, and endothelial and epithelial
cells) and are expressed as inactive zymogens (proenzymes)
containing a propeptide domain that must be removed for
protease activity.2,4,8 In vertebrates, there are at least 28
different MMPs, and at least 23 of them are expressed in
humans.2 Based on their substrate specificities and struc-
tural domains, MMPs can be categorized into one of 6 sub-
groups (Table 2): collagenases (MMP-1, -8, -13, -18);
gelatinases (MMP-2 and MMP-9); stromelysins (MMP-3,
-10, -11); matrilysins (MMP-7, -26); membrane-type
Table 1. Evidence of Matrix Metalloproteinase Involvement in the Pathophysiology of Ocular Diseases
Disease or disorder Experimental evidence of a role of MMPs
Age-related macular
degeneration
Levels of MMP-2 and MMP-9 activity in Bruch’s membrane-choroid tissue samples from
patients with age-related macular degeneration were significantly lower than those in samples
from control eyes113
Bacterial keratitis Upregulation of MMP-9 expression in response to lipopolysaccharide exposure was more
pronounced in primary corneal fibroblasts cultured from patients with bacterial keratitis
compared with fibroblasts cultured from healthy controls; the upregulation of MMP-9 activity
is proposed to be involved in corneal ulceration and perforation114
Choroidal
neovascularization
Studies of the levels of MMPs in choroidal neovascular membranes from patients with age-
related macular degeneration have reported conflicting results115
In a laser-induced rat choroidal neovascularization model, inhibition of MMP-2, MMP-9,
MMP-3, and MT-MMP-1 with the synthetic selective MMP inhibitor prinomastat reduced the
formation of invading fibrovascular lesions116
Climatic droplet
keratopathy
Levels of MMP-2 and MMP-9 were increased in tear samples from patients with climatic droplet
keratopathy compared with normal control patients, suggesting that MMP-2 and -9 could
potentially be involved in the corneal scarring that occurs in the disease117
Corneal
neovascularization
Senescent fibroblasts that accumulate in the corneal stroma in a mouse model of alkali-induced
corneal wound healing and neovascularization show increased expression of MMP-2, -3, and
-14 relative to normal fibroblasts, and in normal mice, injection of hydrogen peroxide-induced
premature senescent fibroblasts promoted corneal neovascularization that was blocked by a
synthetic MMP inhibitor, GM6001118
Diabetic retinopathy Preparations of microvessels from the retina of donors with diabetic retinopathy showed
increased MMP-9 activity, and exposure to glucose stimulated MMP-9 expression in isolated
bovine retinal endothelial cells119
In a rat model of diabetic retinopathy, retinal levels of mRNA for MMP-2, MMP-9, and MMP-
14 were increased; furthermore, exposure to MMP-2 and MMP-9 reduced tight junction
function in cultures of bovine retinal endothelial cells, suggesting that these MMPs might have
a role in the breakdown of the blood–retinal barrier in diabetic retinopathy120
Dry eye disease Corneal epithelium damage in experimentally induced dry eye was attenuated in MMP-9
knockout mice compared with wild-type mice15
Keratoconus Levels of MMP-1, -3, -7, and -13 and collagenase and gelatinase activities were increased in the
tear film of patients with keratoconus compared with controls121
Pseudoexfoliation
glaucoma
Levels of MMP-2 in the aqueous humor were positively correlated with the degree of chamber
angle pigmentation and IOP122
Primary open-angle
glaucoma
Levels of endogenously activated MMP-2 were significantly decreased in aqueous samples from
primary open-angle glaucoma patients compared with cataract control patients47
TIMP-2 levels were significantly increased in patients with primary open-angle glaucoma
compared with cataract control patients48
Pterygium Immunohistochemistry showed the presence of MMP-9, MMP-10, and TIMP-1 in 35%, 34%,
and 72% of pterygial specimens taken from 82 patients123
Inhibition of TIMP-1 gene expression by siRNA in cultures of pterygium epithelial cells resulted
in increased cellular activity in cellular migration and invasion assays123
Spontaneous
autoimmune uveitis
MMP-2 and MMP-14 are decreased and MMP-9 is increased in retinal tissue and vitreous humor
samples from animals with equine recurrent uveitis124
Superior limbic
keratoconjunctivitis
Expression of MMP-1 and MMP-3 was increased in conjunctival specimens and cultured
conjunctival fibroblasts from patients with superior limbic keratoconjunctivitis compared with
controls125
Viral corneal ulcers Polyinosinic-polycytidylic acid, a synthetic analog of viral double-stranded RNA, induced the
expression and secretion of MMP-1 and MMP-3 by cultured human corneal fibroblasts;
expression of MMPs by corneal fibroblasts could be responsible for collagen degradation in
the corneal stroma, leading to corneal ulceration and perforation after viral infection126
IOP, intraocular pressure; MMP, matrix metalloproteinase; MT-MMP, membrane-type MMP; TIMP, tissue inhibitor of metalloproteinase.
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matrix metalloproteinases (MT1/2/3/4/5/6-MMP or MMP-
14, -15, -16, -17, -24, -25); and unclassified MMPs (MMP-
12, -19, -20, -21, -23, -27, -28).9
Many of the MMPs are secreted as proenzymes and are ac-
tivated extracellularly.2 However, MMP-11, -21, and -28 and the
MT-MMPs have a furin-like proprotein convertase recognition
sequence at the C-terminus of the propeptide, and these proen-
zymes are activated intracellularly by furin.2 After the MT-
MMPs are activated intracellularly, they are transported to the
cell surface where they can cleave and activate other proMMPs.2
FIG. 1. Role of MMPs in
physiologic (A) and patho-
logic conditions (B).2,8,19,112
MMP, matrix metalloprotei-
nase.
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During normal steady-state conditions, levels of MMPs
in most tissues are low or negligible.10 MMP expression is
transcriptionally controlled by inflammatory cytokines,
growth factors, hormones, and cell–cell and cell–matrix in-
teractions. Activation of the proenzyme to the active form
can be mediated by endopeptidases such as furin, serine
proteases, or other MMPs.8 For example, MT1-MMP can
activate proMMP-2.11 Activity of the MMPs is further reg-
ulated by 2 major types of endogenous inhibitor, a2-
macroglobulin and tissue inhibitors of metalloproteinase
(TIMPs).4,10 The a2-macroglobulin inhibitors are confined
to the blood and lymph and result in irreversible clearance
of MMPs through endocytosis of a2-macroglobulin/MMP
complexes.12 Four homologous TIMPs (TIMP-1, -2, -3, and
-4) have been identified; each binds MMPs in a 1:1 stoichi-
ometry and leads to reversible inhibition of MMPs.12 Each
TIMP can inhibit multiple MMPs with varying specificity and
affinity,2,9 and the ratio of MMP:TIMP often determines the
extent of ECM turnover.2
Alterations in MMP expression and activity occur in
normal biological processes (eg, wound healing), but im-
balances in the ratio of MMP and TIMP levels can cause
abnormal tissue remodeling due to the excessive degrada-
tion or accumulation of ECM components and changes in
growth factors, receptor signaling, and cell migration.2,13
Such imbalances contribute to pathological conditions such as
cardiovascular disease (eg, atherosclerosis), musculoskeletal
disorders (eg, arthritis), neurodegenerative diseases (eg, Alz-
heimer’s, Parkinson’s), and various cancers (Fig. 1B).2,14
Evidence suggests that MMPs are involved in the inflam-
mation, angiogenesis, and degenerative processes that occur in
several ocular diseases. For example, levels and activity of
MMP-9 in the tear film have been shown to be elevated in
patients with dry eye disease, and studies of experimentally
induced dry eye in MMP-9 knockout and wild-type mice have
demonstrated that MMP-9 participates in the destruction of
the corneal epithelium caused by dry eye.15 Studies using
MMP-2 and MMP-9 knockout and wild-type mice have fur-
ther implicated both MMP-2 and MMP-9 in the development
of choroidal neovascularization induced by laser-induced
rupture of Bruch’s membrane in a mouse model of neovas-
cular age-related macular degeneration.16
Efforts to exploit MMPs in the treatment of disease typically
have focused on inhibiting MMP activity. Broad-spectrum
synthetic inhibitors of MMPs have been tested in various types
of cancer, and use of inhibitors of specific MMPs remains a
viable potential strategy to reduce tumor metastasis.17,18 MMP
inhibition also has been proposed as a therapeutic approach for
diabetic foot ulcers and currently is utilized in the treatment
of periodontal disease.19 In contrast, PGAs that increase MMP
activity have proven to be useful in the treatment of glaucoma.
Glaucoma is treated by lowering IOP, and increasing MMP
activity in target intraocular tissues for IOP lowering causes
ECM remodeling that results in a decrease in IOP.
Glaucoma, Aqueous Outflow
Pathways, and MMPs
Glaucoma is a progressive optic neuropathy and the leading
cause of irreversible blindness. It is estimated to affect 3.5%
of the global population aged between 40 and 80 years.20 IOP
is the major modifiable risk factor for the onset and progres-
sion of glaucoma, and there is overwhelming evidence that
reducing IOP has a protective effect on the visual field in
glaucoma, even when IOP is already in the normal range.21–23
As a consequence, treatment modalities for glaucoma, whe-
ther surgical or pharmaceutical, are aimed at lowering IOP.
Normal IOP ranges between 10 and 21 mm Hg24 and is
maintained through regulation of the production and outflow of
aqueous humor, which supplies oxygen and glucose to the
avascular lens, cornea, iris, and trabecular meshwork (TM) of
the eye. Although the secretion of aqueous humor by the ciliary
body and its drainage through the unconventional outflow
pathways (uveoscleral and uveovortex) are relatively pressure
insensitive, outflow through the conventional (trabecular)
pathway is pressure dependent, and IOP is determined in large
part by the resistance generated in the conventional outflow
pathway (Fig. 2), where the majority of aqueous humor exits
the eye.25–28 An early study using a tracer method to directly
measure uveoscleral outflow in 2 human eyes reported that
<15% of the total aqueous outflow occurred through the
uveoscleral pathway.29 Although studies using indirect meth-
ods to assess unconventional outflow have varied widely, they
most frequently have reported that it accounts for 25%–50% of
the total aqueous outflow in human eyes.28 Disparate findings
among and within studies have been attributed to differing
methodologies (use of tonographic or fluorophotometric mea-
surement of outflow facility, and assumed episcleral venous
pressure) and to an age-related decrease in unconventional
outflow.28,30
The TM is a porous tissue with 2 regions involved in filtering
aqueous with minimal impedance: the uveal meshwork and the
corneoscleral meshwork.31 In contrast, the third region of the
TM, the deepest one, the juxtacanalicular tissue (also known as
the cribriform region) generates outflow resistance through
interactions with the inner wall of Schlemm’s canal.27 The
uveal and corneoscleral meshworks are composed of connec-
tive tissue beams and sheets/lamellae, with large intertrabecular
spaces between adjacent sheets.32 Aqueous humor drains
through the intratrabecular spaces of the TM and the loosely
arranged ECM of the juxtacanalicular tissue and is removed
through the Schlemm’s canal into collector channels, and from
there into aqueous veins and the episcleral venous system.31,32
Increased IOP in primary open-angle glaucoma is caused by an
increase in aqueous humor outflow resistance, measured as a
decrease in tonographic outflow facility,33 which leads to a
decrease in pressure-sensitive outflow. Enhancing outflow
through the TM pathway is a recognized approach for lowering
IOP in glaucoma, both to correct the deficit that causes elevated
IOP and to allow the eye to recover from transient pressure
disturbances (eg, increased pressure from a pillow pressing
against the eye during sleep).33
The ECM of the juxtacanalicular region participates in the
generation of resistance to aqueous humor outflow through
the TM pathway.31 The ECM of the TM consists of collagens,
laminins, elastin, fibronectin, fibrillins, and proteoglycans34
and is continuously being remodeled by members of the
MMP family (eg, MMP-1, -2, -3, -9, -12, and -14).12 Studies
using perfused human anterior segment organ cultures and
human TM cell cultures have shown that increases in IOP
cause an increase in MMP-2 expression, and mechanical
stretching of TM cells causes an increase in MMP-2 ex-
pression and a decrease in TIMP-2 expression.35 These re-
sults support a hypothesis of a feedback mechanism for IOP
homeostasis,35 in which TM cells sense an increase in IOP
through stretch/distortion of the ECM, and they respond by
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increasing MMP and decreasing TIMP expression. This re-
sults in enhanced ECM turnover, which causes a decrease in
the TM resistance to aqueous humor outflow and a decrease
in IOP, restoring IOP to normal levels.
Early evidence for MMPs producing ECM remodeling that
enhances aqueous humor outflow through the TM was pro-
vided by a study using perfused human anterior segment
organ cultures.36 The addition of recombinant MMP-2,
MMP-3, or MMP-9 resulted in a reversible increase in out-
flow facility, whereas inhibition of endogenous MMP activity
reduced outflow facility.36 More recently, altered structural
organization of the TM and early-onset ocular hypertension
were observed in MMP-9 knockout mice, suggesting that
remodeling of the TM by MMP-9 is needed to enhance
outflow and maintain IOP homeostasis.37
Studies of the mechanisms of steroid-induced increased IOP
and glaucoma have also provided evidence of the involvement
of MMPs in IOP regulation. Enhanced juxtacanalicular depo-
sition of fibrous material has been observed with electron mi-
croscopy in tissue samples from patients with corticosteroid-
induced glaucoma.38 The accumulation of ECM components as
a contributing mechanism in steroid-induced glaucoma was
supported by the findings from studies investigating the effects
of corticosteroids in cell cultures39,40 and animal models.41,42
Exposure of TM organ cultures to corticosteroids led to a de-
crease in extracellular protease activities, including 92 kDa type
IV collagenase activity (MMP-9).39 In another study using
human corneoscleral explant cultures containing both ciliary
body and TM, exposure to dexamethasone led to decreased
activity of MMP-2, MMP-3, and MMP-9 on zymography.40
Long-term treatment with a corticosteroid in a primate model
resulted in structural changes in the TM consistent with
steroid-induced glaucoma, including increased ECM depo-
sition in the juxtacanalicular region41 (Fig. 3). Finally, in a
sheep model of steroid-induced ocular hypertension, gene
therapy with a vector carrying an inducible MMP-1 human
gene protected against and reversed corticosteroid-induced
IOP increases.42 Together these findings suggest that corti-
costeroids downregulate MMPs in the TM (and possibly also
in the ciliary body), leading to ECM deposition and tissue
remodeling that reduces aqueous outflow and leads to in-
creased IOP.
Uveoscleral outflow involves the resorption of aqueous
humor through the intercellular spaces of the ciliary muscle
FIG. 2. Anatomy of the eye and aqueous humor outflow pathways. Aqueous humor is produced by the ciliary body and
moves through the pupil into the anterior chamber where it exits the eye. In the conventional outflow pathway, the aqueous
filters through the TM into the lumen of Schlemm’s canal, which drains into aqueous veins and the episcleral venous
system. In the unconventional outflow pathway, aqueous drains through the ciliary muscle, supraciliary and suprachoroidal
spaces, and sclera. TM, trabecular meshwork.
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into the suprachoroidal space, with transscleral flow occur-
ring through interfibrillary and perivascular spaces of the
scleral stroma.43 Compaction of the scleral ECM affects
transscleral permeability.44 As collagen accounts for 75% of
the total dry weight of sclera,44 collagen density within the
sclera can be expected to affect permeability,45 and MMP
collagenase activity in the sclera is very likely to cause
tissue remodeling that enhances transscleral outflow. In
addition, immunohistochemistry studies have shown the
presence of MMP-1 in tissues associated with the uveo-
scleral outflow pathway in normal human eyes (ciliary
muscle, iris root, and sclera), suggesting that MMP-1 ac-
tivity may be a key regulator of uveoscleral outflow.46
In a study evaluating aqueous humor concentrations of
MMPs and TIMPs, levels of endogenously activated MMP-
2 were reported to be significantly decreased in aqueous
samples from primary open-angle glaucoma patients com-
pared with cataract control patients, while levels of TIMP-2
were unchanged.47 In contrast, in a similar study that eval-
uated aqueous humor concentrations of MMP-2 and TIMP-
2, TIMP-2 levels were significantly increased in patients
with primary open-angle glaucoma compared with cataract
control patients.48 Importantly, the results of both studies
suggest that an imbalance in the MMP/TIMP ratio may
contribute to the pathogenesis of decreased outflow facility
and elevated IOP in glaucoma.47,48
Topical PGAs in Glaucoma Management
The first topical PGA for IOP lowering, latanoprost, was
introduced in the 1990s. Over the past 2 decades, topical
PGAs have become commonly used first-line glaucoma
therapies because they reduce IOP more effectively than
other classes of topical ocular hypotensive medications49 and
are well tolerated and systemically safe.50 Common side
effects include conjunctival hyperemia, eyelash changes, and
hyperpigmentation of the iris and periocular skin.50 PGA eye
drops, which are instilled once daily, include prostaglandin
(PG) ester prodrugs (latanoprost, travoprost, tafluprost) and
the prostamide, bimatoprost. The prodrugs are quantitatively
hydrolyzed by esterases in the cornea into their biologically
active free acid forms.51 Bimatoprost is less efficiently hy-
drolyzed by corneal amidases.51 Both the intact bimatoprost
molecule and bimatoprost free acid have biological activi-
ty52–54 and are present in ocular tissues after topical bima-
toprost administration,51 and both the intact bimatoprost
molecule and the free acid have been proposed to contribute
to the IOP-lowering effects of topical bimatoprost.51,55–58
The PGAs lower IOP by enhancing aqueous outflow,59 and
latanoprost, bimatoprost, and travoprost consistently have
been reported to increase outflow through the uveoscleral
pathway.60 However, the methods used for measurement
of outflow facility in human eyes are imprecise and have
influenced findings of the relative contribution of enhanced
pressure-sensitive and pressure-insensitive outflow to the
IOP lowering produced by topical PGAs.59 Bimatoprost has
been reported to have a dual mechanism of action, reducing
IOP by enhancing both pressure-insensitive (presumed
uveoscleral) and pressure-sensitive (presumed TM) out-
flow. The enhancement of pressure-sensitive outflow was
primarily responsible for the reduction of IOP produced
by topical bimatoprost in normal subjects.33
On a molecular level, the enhancement of aqueous outflow
by PGAs is believed to involve MMP-mediated increased
turnover of the ECM in the uveoscleral and TM aqueous out-
flow pathways, leading to reduced outflow resistance.60
Evidence Implicating MMPs in the Mechanism
of Action of Topical PGAs
An early study from the 1980s using cynomolgus mon-
keys61 suggested that ECM turnover in the ciliary body was
critically involved in the mechanism of IOP lowering with
topical PGAs.61 The increase in uveoscleral outflow facility
produced by PGA treatment was associated with pro-
nounced changes in extracellular material within the ciliary
muscle (Table 3), which were suspected to result from
collagenolytic activity described with PGAs in other organs.
A study using human ciliary smooth muscle cells exposed to
PGF2a for 3 days provided supporting evidence that MMPs
were involved in the ECM turnover: concentrations of
FIG. 3. Electron micrographs of the TM of primates treated for 1 year with placebo (A) or systemic corticosteroid
(B). The control animals showed normal TM morphology. In contrast, the TM in animals treated with corticosteroid
demonstrated an increase in ECM in the juxtacanalicular region. This accumulation of ECM increases the hydraulic
resistance to aqueous outflow leading to elevated IOP. Scale bars, 10mm. Arrows show increased ECM. Republished from
Clark et al.41 with permission. ª ARVO (Association for Research in Vision & Ophthalmology). ECM, extracellular
matrix. IOP, intraocular pressure.
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Table 3. Key Studies of the Effects of Prostaglandin-Related Compounds on Matrix Metalloproteinase
Expression and the Morphology of Aqueous Humor Outflow Pathways
Study PG or PGA
Experimental
model
Duration of
exposure Effects
Uveoscleral tissues
Lu¨tjen-Drecoll
et al.61
PGF2a tromethamine
salt, PGF2a
isopropyl ester
Cynomolgus
monkeys
Once or twice
daily topical
treatment for
4–8 days
Ciliary muscle showed empty
spaces between muscle fiber
bundles, and loss of reticular
fibers and ground substance in the
enlarged spaces could be
responsible for the increase in
uveoscleral outflow
Lindsey et al.62 PGF2a, 17-
phenyltrinor-PGF2a,
11-deoxy-PGE1
Human ciliary
smooth muscle
cells
Exposure for 1–3
days
Increased proMMP-1 and -3
concentrations in the culture
medium
Weinreb
et al.63
PGF2a, 17-
phenyltrinor-PGF2a,
11-deoxy-PGE1,
latanoprost acid
Human ciliary
smooth muscle
cells
Exposure for 1–3
days
Increased concentration of MMP-1,
-2, -3, and -9 in the culture
medium
Sagara et al.127 PGF2a-isopropyl ester Cynomolgus
monkeys
Twice daily topical
treatment for
5 days
Significant reductions in scleral
collagen (most notably type I and
III) immunoreactivity in the
ciliary muscle and adjacent sclera
Kim et al.64 Latanoprost acid,
PGF2a, 17-
phenyltrinor-PGF2a
Human scleral
organ cultures
Exposure for 24,
48, or 72 h
Increased transscleral permeability
accompanied by increased MMP
expression (MMP-2 > MMP-3 >
MMP-1)
Gaton et al.65 PGF2a-isopropyl ester Cynomolgus
monkeys
Twice daily topical
treatment for 5
days
Significant increase in MMP (-1, -2,
and -3) expression in tissues of
uveoscleral outflow pathway
Weinreb and
Lindsey66
Latanoprost acid Human ciliary
smooth muscle
cells
Exposure to
concentrations
of 8–1,000 nM
for 24 h
Concentration-dependent increases
in MMP-1, -3, and -9 mRNA
levels
Anthony
et al.67
Latanoprost acid Human ciliary
smooth muscle
cells
Exposure to
concentrations
of 1–1,000 nM
for 6, 18, or 24 h
Concentration- and time-dependent
increase in TIMP-1 protein and
TIMP-1 mRNA levels, brief and
minor increase in TIMP-2 protein
Richter et al.76 Bimatoprost 0.03%,
latanoprost 0.005%,
sulprostone 0.03%,
AH13205 0.1%
Cynomolgus
monkeys
Topical treatment
for 1 year
Enlarged and more organized
spaces between muscle bundles
of ciliary muscle for outflow;
doubling in number of nerve fiber
bundles in ciliary muscle
Hinz et al.128 Latanoprost acid Human
nonpigmented
ciliary
epithelial cells
Exposure for 24 h Increase in COX-2 mRNA
expression leading to increased
levels of PGE2 in culture
medium and increased expression
of MMP-1 mRNA
Oh et al.68 Latanoprost acid Human ciliary
body tissue
and smooth
muscle cells
Exposure for 24 h Upregulation of MMP-3, -9 (low
expression), -17, TIMP-3 mRNA
expression; downregulation of
MMP-1, -2, -12, -14, -15, -16,
TIMP-4 mRNA expression
Ooi et al.86 Bimatoprost acid,
latanoprost acid,
unoprostone acid
Human ciliary
body smooth
muscle cells
isolated from
donor
corneoscleral
rims
Exposure for 24 h The different PGAs produced
different ratios of MMP/TIMP,
potentially related to their
differences in intraocular pressure-
lowering efficacy; for example, all
PGAs increased MMP-1, -3, and
-9; MMP-2 levels were decreased
by unoprostone and unaffected by
bimatoprost and latanoprost; and
all PGAs increased TIMP-3, but
only unoprostone increased
TIMP-1 and -4
(continued)
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proMMP-1 and -3 in the culture medium were increased by
254% and 128%, respectively, and similar increases were
observed after exposure to other PGs.62
In a follow-up study, cultured human ciliary smooth
muscle cells were incubated with latanoprost acid, PGF2a,
17-phenyltrinor-PGFa, or 11-deoxy-PGE1 (Fig. 4 and
Table 3).63 MMP protease activity in the medium was as-
sayed using gelatin and casein zymography, and Western
blot results confirmed that the bands in the zymographs were
MMP-1, -2, -3, and -9. Exposure to the PGs for 72 h in-
creased levels of activity for all 4 MMPs compared with
vehicle, confirming that MMP release is altered by exposure
to PGs (Fig. 4).63 To further elucidate the effect of PGs on
MMPs and its relationship to changes in uveoscleral out-
flow, these investigators incubated human scleral tissue with
PGs and measured scleral permeability by evaluating per-
fusion of dextrans across the scleral tissue with a 2-chamber
Ussing apparatus.64 PGF2a and PGAs (including latano-
prost acid) increased tissue permeability in a time- and
concentration-dependent manner, and the increase in per-
meability was associated with increases in the expression of
MMPs (MMP-2 > MMP-3 > MMP-1) as measured by an
enzyme-linked immunosorbent assay.64
Evidence of alterations in MMP expression, associated
with IOP lowering in response to a topical PGA, was sub-
sequently confirmed in primates.65 Immunoreactivity for
MMPs (-1, -2, and -3) in iris root, ciliary muscle, and ad-
jacent sclera was significantly increased after topical treat-
ment of cynomolgus monkeys with PGF2a-isopropyl ester
for 5 days in comparison with contralateral vehicle-treated
eyes.65 Importantly, the intensity of immunostaining for
MMP-2 in the ciliary muscle was significantly associated
with the magnitude of the IOP reduction.65
The same group also investigated whether the PGA-
induced increased MMP expression by ciliary body muscle
cells was preceded by changes in MMP mRNA levels,
suggesting transcriptional regulation of MMP expression, as
had been reported in other cell types.66 Total RNA was
isolated from cultured human ciliary smooth muscle cells,
and the expression of mRNAs for MMP-1, -2, -3, and -9 was
determined using real-time polymerase chain reaction (RT-
PCR) assays. Latanoprost acid induced a concentration-
dependent upregulation of MMP-1 (3- to 13-fold), -3, and -9
mRNA levels and no change in MMP-2 mRNA levels
compared with mRNA levels in vehicle-treated cultures.66
In another study using cultured ciliary muscle cells, the in-
duction of MMP-1 and -2 expression and activity by latanoprost
acid was found to be accompanied by a simultaneous induc-
tion of TIMP-1.67 Concentration- and time-dependent increases
in TIMP-1 protein appeared on Western blot analysis of human
Table 3. Continued
Study PG or PGA
Experimental
model
Duration of
exposure Effects
Trabecular meshwork and aqueous humor
Richter et al.76 Bimatoprost 0.03%,
latanoprost 0.005%,
sulprostone 0.03%,
AH13205 0.1%
Cynomolgus
monkeys
Topical treatment
for 1 year
Disconnection of some endothelial
cells of the inner wall of
Schlemm’s canal from the
subendothelial layer, with loss of
ECM underneath the endothelium
and through the juxtacanalicular
region
Oh et al.69 Latanoprost acid Human TM
tissue and
endothelial
cells
Exposure for 24 h Increase in mRNA expression of
MMP-1, -3, -17, -24 and decrease
in mRNA expression of MMP-11
and -15; upregulation of TIMP-2,
-3, -4
Wan et al.58 Bimatoprost Human anterior
segments and
TM cells
Increase in outflow facility by 40%
on average; increase in hydraulic
conductivity of trabecular
meshwork cell monolayers by
78%
Bahler et al.70 Latanoprost acid, PGE1 Cultured human
anterior
segments,
including TM
and Schlemm’s
canal
Continuous
infusion up to
72 h
Focal detachment and loss of
Schlemm’s canal cells; no
consistent change in MMP-2, -3,
or -9 activity in the anterior
segments
Yamada et al.87 Bimatoprost acid,
latanoprost acid,
tafluprost acid
Human
nonpigmented
ciliary
epithelial cell
cultures
Exposure for 24 h Each PGA induced a concentration-
dependent increase in mRNA
levels for MMP-1, -2, -3, -9, and
-17 and decrease in mRNA levels
for TIMP-1 and -2
Adapted from Toris et al.60 Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction, S107–120,
Copyright ª 2008, with permission from Elsevier.
COX-2, cyclooxygenase-2; ECM, extracellular matrix; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; TM,
trabecular meshwork; PG, prostaglandin; PGA, prostaglandin analog/prostamide.
ciliary muscle cells incubated with latanoprost acid, and
TIMP-1 mRNA levels were also upregulated.67 Induction of
TIMP mRNA with latanoprost acid was corroborated in a
subsequent study in which MMP and TIMP mRNA levels were
evaluated with a long-term goal of identifying those that are
associated with the observed increased uveoscleral outflow.68
Latanoprost acid effects on MMP and TIMP mRNA expression
in cultures of ciliary smooth muscle cells from human donors
varied somewhat by donor, but exposure to latanoprost acid
induced MMP-9 mRNA expression and caused increased ex-
pression of mRNA for MMP-3 (in 3 of 5 cultures), MMP-17
(in 4 of 5 cultures), and TIMP-3 (in all 5 cultures) and decreased
expression of mRNA for MMP-1 (in all 5 cultures), MMP-2
(in 3 of 5 cultures), and TIMP-4 (in 2 of 5 cultures).68 The
authors suggested that coordinated expression of MMP-3, -9,
and -17 along with TIMP-3 might mediate the alteration of the
ECM with latanoprost treatment.68
The effects of PGA treatment on MMP and TIMP ex-
pression in the TM, as well as the ciliary body, were in-
vestigated in a study using human corneoscleral explant
cultures.40 After 72 h of incubation with latanoprost, levels
of MMP-2, MMP-3, and MMP-9 in the medium were in-
creased by 36%, 112%, and 156%, respectively, as mea-
sured by zymography. Immunohistochemistry showed
increased staining for the MMPs after latanoprost exposure
in the ciliary body, but not in the TM. No increase in staining
for TIMP-1 or TIMP-2 was evident in either tissue.40 In a
later study evaluating the effect of latanoprost on MMPs and
TIMPs in the TM, mRNA for several MMPs (MMP-1, -2,
-3, -11, -12, -14, -15, -16, -17, -19, and -24) and TIMPs (-1 to
-4) was identified using RT-PCR in human TM tissue and in
cultures of TM cells from human donors.69 Exposure of the
cultures from some donors to latanoprost acid caused in-
creased expression of mRNA for MMP-1, -3, -17, and -24
and TIMP-2, -3, and -4. The authors suggested that TIMP
upregulation with latanoprost acid might possibly occur to
compensate for the increase in MMPs.69 In contrast, in a
study using 6 different TM cell strains isolated from human
donor eyes, exposure for 24 h to a high concentration of bi-
matoprost caused increased expression of mRNA for MMP-1,
MMP-10, MMP-11, MMP-14, and MMP-16 and decreased
expression of TIMP-3 mRNA (Stamer et al. International So-
ciety for Eye Research/BrightFocus Foundation 2nd Glaucoma
Symposium, Oct. 23–26, 2019; Atlanta, GA).
The results from the cell culture studies suggest that PGA
exposure affects the expression of MMPs by TM cells, al-
though the response among cell strains is variable. In 2 separate
studies using perfused human anterior segments in organ cul-
ture to test conventional outflow separately from the uveoscl-
eral pathway, bimatoprost58 and latanoprost acid and PGE170
were found to significantly increase conventional outflow fa-
cility. In the first study, bimatoprost gradually increased out-
flow facility over 2 days of exposure,58 suggesting the
possibility that the change in outflow facility might be mediated
by changes in the ECM in the juxtacanalicular region. In the
second study, histological assessments of the tissue after lata-
noprost acid treatment demonstrated significant remodeling
characterized by a focal loss of Schlemm’s canal endothelial
cells as they were lifted off the basal lamina, consistent with
loosening of the focal adhesions between the cells and the
ECM.70 In 2 of the organ cultures, the endothelial cell loss was
accompanied by focal loss of underlying ECM in the juxtaca-
nalicular tissue.70 Although MMPs evaluated by Western blot,
zymography, and immunohistochemistry were not consistently
increased after latanoprost acid treatment of the organ cultures,
and the early onset of the increase in outflow facility suggested
that a mechanism in addition to upregulation of MMPs could be
involved, one of 10 pairs of anterior segments showed an in-
crease in MMP-3 on both Western blots and zymography.70
Upregulation of MMP activity and ECM turnover in the
TM similarly has been implicated in the increase in outflow
facility and decrease in IOP produced by adenosine A1 ago-
nists.71,72 For example, trabodenoson, an adenosine mimetic
with A1 selectivity, has been shown to increase MMP-2
activity and decrease fibronectin and collagen IV levels in
3-dimensional human TM cell cultures and has also been
shown to increase outflow facility and lower IOP in young and
aged mice.72 In addition, the ADAMTS (a disintegrin and
metalloproteinase with thrombospondin motifs) family of ex-
tracellular proteases, related to the MMP family, also remodels
FIG. 4. Increase in MMP activity in the culture medium of human ciliary muscle cells after PG exposure. (A) Third-
passage human ciliary muscle cells from a 59-year-old eye form a monolayer with aligned spindle-shaped cells. (B) Gelatin
zymogram of media from cells exposed for 72 h to vehicle control (lane 1) or to 200 nM PGF2a (lane 3), 17-phenyltrinor-
PGF2a (lane 4), 11-deoxy-PGE1 (lane 5), or latanoprost acid (lane 6). Band sizes increased in medium from PG-treated
cultures, indicating increased MMP activity. Used with permission of ARVO, from Weinreb et al.63; permission conveyed
through Copyright Clearance Center, Inc. PG, prostaglandin.
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the ECM,73 and treatment with recombinant ADAMTS-4 has
been shown to increase outflow facility in cultured porcine and
human anterior segments.74 ADAMTSs potentially could be
involved in the mechanism of IOP lowering by PGAs down-
stream of MMP upregulation, as MMP-17 has been shown to
activate ADAMTS-4.75
Morphological changes indicative of ECM remodeling in
both the ciliary muscle and TM were demonstrated in cyno-
molgus monkeys after long-term treatment with PGAs. Pri-
mate eyes were treated with topical bimatoprost, latanoprost,
an EP2 agonist (AH13205), an EP3/EP1 agonist, or vehicle
at IOP-lowering doses for 1 year.76 Sections from the 4
quadrants of the circumference of the eyes were investigated
qualitatively and quantitatively using light and electron
microscopy. Tissue remodeling was apparent and similar in
all 4 active treatment groups, and included significant in-
creases in optically empty spaces between muscle bundles in
the anterior ciliary muscle (Fig. 5), as well as an increase in
myelinated nerve fiber bundles. In contrast to the study from
the 1980s that used short-term PGA treatment, there was not
simply a loss of ECM but, rather, an organized remodeling
was seen, in which the increased spaces among ciliary
muscle bundles were incompletely lined with endothelial-
like cells and presumably represented new uveoscleral
outflow routes (Fig. 5). There was also remodeling in the
TM, including disruption of the endothelial cell monolayer
of Schlemm’s canal, expansion of the juxtacanalicular re-
gion of the TM, loss of ECM, and, in some samples, wid-
ening of intertrabecular spaces in the corneoscleral region of
the TM,76 all of which could potentially contribute to an
increase in outflow facility.
Another study in cynomolgus monkeys similarly showed
remodeling of the ciliary body, with apparent formation of
new outflow channels, after 1 year of topical treatment with
the prostaglandin EP2 agonist butaprost.77 TM remodeling
(Fig. 6), including expansion of the juxtacanalicular region,
enlargement of the collector channels and their connections
to Schlemm’s canal, disconnection of some TM cells from
FIG. 5. Electron micrographs of sagittal sections through the
anterior longitudinal portion of the ciliary muscle of cyno-
molgus monkeys after 1 year of topical treatment with bima-
toprost. Ciliary body remodeling after bimatoprost treatment
included enlarged spaces for outflow between muscle bundles
in the anterior ciliary muscle that were partially lined with
endothelial-like cells (arrows in A). Capillaries within the en-
larged intermuscular spaces had a thickened basement mem-
brane (arrow in B) in contact with some endothelial-like cells.
Used with permission of ARVO, from Richter et al.76; per-
mission conveyed through Copyright Clearance Center, Inc.,
Scale bars: (A) 2mm; (B) 1mm. C, capillary; M, muscle fiber
bundles; N, nerve fiber.
FIG. 6. Sagittal sections through the TM of cynomolgus
monkeys after 1 year of topical treatment with butaprost.
Remodeling was evident in (A) and more pronounced in
(B). The juxtacanalicular region was widened and showed
focal disconnections from the inner wall endothelium of
Schlemm’s canal (arrows); several lamellae were reduced in
thickness or nearly eliminated (arrowheads). Used with
permission of ARVO, from Nilsson et al.77; permission
conveyed through Copyright Clearance Center, Inc., CC,
collector channel; SC, Schlemm’s canal.
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the endothelial lining of Schlemm’s canal and the underly-
ing ECM, and reduction in some TM lamellae, was evident
in many of the animals.77 MMP expression was not evalu-
ated in either of the primate studies, but a transient or sus-
tained increase in MMP activity could account for the
remodeling seen in the primate outflow tissues after long-
term topical PGA treatment.
A recent pharmacogenetic study has provided further
support for the involvement of MMPs in the mechanism of
IOP lowering with PGAs.78 In a case–control study of 117
Spanish patients with open-angle glaucoma, candidate genes
(MMP genes and the PGF2a receptor gene, PTGFR) and
single-nucleotide polymorphisms (SNPs) of the genes were
investigated for a potential relationship to responsiveness to
latanoprost treatment. Although only SNPs of PTGFR were
identified as being associated with positive or negative re-
sponses to latanoprost, subhaplotype analysis identified 6
subhaplotypes of the MMP-1 gene associated with no re-
sponse to latanoprost.78 These findings strongly implicate
MMP-1 in the mechanism of IOP lowering with PGAs.
Activation of MMPs by Topical PGAs
in Nontarget Ocular Tissues
Activation of MMPs in the TM and the ciliary body target
tissues appears to be an essential component of the mecha-
nism of IOP lowering for the topical PGAs. However, PGA
eye drops also upregulate MMPs in ocular tissues unrelated
to IOP lowering. In a study using rabbits, conjunctival
subepithelial collagen was increased in timolol-treated eyes
compared with latanoprost-treated and control eyes, and im-
munostaining revealed the presence of conjunctival MMP-3
only in the latanoprost-treated eyes.79 Similarly, in a study
using conjunctival specimens from human eyes treated with
topical latanoprost or timolol, immunostaining showed greatly
increased expression of MMP-1 and MMP-3 and moderately
increased expression of TIMP-2 and TIMP-3 in epithelial cells
and subepithelial stromal cells of latanoprost-treated eyes, and
this was accompanied by a marked reduction in the stromal
collagen density in the latanoprost-treated eyes relative to the
timolol-treated eyes.80 The results of both studies suggest that
PGA-induced increased MMP activity in the conjunctiva
might help prevent treatment-related changes in the conjunc-
tival ECM that contribute to failure of filtering blebs.79,80
The expression of MMPs in the cornea has been studied
extensively as it relates to corneal wound healing.1 Because
the stroma of the cornea is largely composed of collagen,
MMP activation in the cornea might be expected to cause
stromal ECM remodeling and corneal thinning. The effects
of topical IOP-lowering medications, including the PGAs, on
central corneal thickness (CCT) have been well studied
because of the known effect of CCT on IOP measurements,
that is, IOP measured with Goldmann applanation is under-
estimated in eyes with thinner CCT and overestimated in eyes
with thicker CCT.81 A meta-analysis of CCT data from eyes
with chronic disease has suggested that a change in CCT of
20mm is associated with a change of 1 mm Hg in measured
IOP.24 Topical treatment with PGAs has been shown to
produce small but consistent reductions in CCT82,83: a re-
duction in mean CCT from baseline of 11 and 16mm has been
reported in glaucoma patients after 2 years of treatment with
latanoprost and bimatoprost, respectively.82
The reduction in CCT following topical PGA treatment
has been attributed to upregulation of MMPs in the corneal
stroma and MMP-mediated tissue remodeling.82 This con-
cept is supported by a study using cultured porcine corneal
stroma cells, in which 90-min exposure to latanoprost led to
changes in cell shape and an *50% decrease in intact fi-
bronectin (an ECM component and substrate of MMPs,
particularly MMP-13 and -14) in the cultures.84
The reduction in CCT associated with topical PGA
treatment has no deleterious effects, but it may be of par-
ticular interest, because CCT reduction could potentially be
a surrogate marker for increased MMP activity in outflow
tissues. Moreover, the IOP in response to topical PGAs may
be underestimated with a thinner cornea.
Profiles of MMP Expression Vary by PGA
Clinical trials have shown some differences in efficacy
among the topical PGAs, and in a network meta-analysis of
randomized controlled trials that compared a single topical
IOP-lowering medication with another medication or no
treatment/vehicle, the relative efficacy of the topical PGAs
was bimatoprost > latanoprost & travoprost > tafluprost >>
unoprostone.85 Differences in the MMP activation profiles of
the individual PGAs may contribute to their differing efficacy.
In a study testing the effects of the free acids of bima-
toprost, latanoprost, and unoprostone on the expression of
MMPs and TIMPs in cultured human ciliary muscle cells,
all of the PGAs increased the expression of MMP-1, -3, and
-9, as well as TIMP-3, but only unoprostone acid decreased
MMP-2 expression and increased the levels of TIMP-1 and
-4. The differing effects of the PGAs on the MMP/TIMP
balance reflect the relative effectiveness of the PGAs in
lowering IOP, with unoprostone associated with both the
lowest ratio of MMPs to TIMPs and the lowest efficacy of
the PGAs.86 In a second study testing the effects of the free
acids of bimatoprost, latanoprost, and tafluprost in human
nonpigmented ciliary epithelial cell cultures, all of the PGAs
increased mRNA levels for MMPs, but at equivalent con-
centrations, bimatoprost acid produced a greater increase in
MMP-2 and MMP-3 mRNA levels compared with latano-
prost acid and tafluprost acid.87 The results of both studies
are consistent with a premise that greater efficacy of a PGA
could result from greater upregulation of MMP expression
and activity in ECM turnover.
PGA Effects on MMPs Are
Concentration Dependent
There is ample evidence that the upregulation of MMPs
by PGAs is dependent not only on the identity of the PGA
but also on its concentration. In an early study using human
explant scleral cultures, the effects of latanoprost acid on
MMP-3, MMP-10, MMP-14, TIMP-1, TIMP-2, and TIMP-3
mRNA expression were shown to be concentration depen-
dent.88 Similarly, exposure to latanoprost acid affected the
expression of mRNA for various MMPs and TIMPs in a
study using cultured ciliary muscle cells from human do-
nors.68 In the latter study, the direction and magnitude of
effect were influenced by the cell source (donor), the par-
ticular MMP or TIMP, and the drug concentration at phar-
macological and higher concentrations.68
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In a more recent study using human cultured non-
pigmented ciliary epithelial cells, levels of mRNA for
MMPs and TIMPs were measured after the cultures were
exposed to the free acid of latanoprost, bimatoprost, or ta-
fluprost at concentrations from 10mM to 1 mM.87 All 3
PGAs caused a dose-dependent increase in mRNA levels for
each of the MMPs evaluated (MMP-1, -2, -3, -9, and -17) and
a dose-dependent decrease in mRNA levels for TIMP-1 and
TIMP-2.87 For bimatoprost acid, the highest tested concen-
tration produced MMP mRNA levels up to 45-fold higher
than those with the lowest tested concentration (Fig. 7).
These findings suggested to us that a high PGA concen-
tration in outflow tissues might be able to affect the
MMP/TIMP balance in a manner that produces greater
MMP activity and a more sustained IOP lowering.
Exploiting MMPs in Glaucoma Therapy:
Development of a Bimatoprost Implant
Providing Sustained IOP Lowering
A well understood limitation in the use of topical PGAs,
and indeed all topical medications, for treatment in glaucoma
is poor adherence of patients to eye drop regimens. Studies
using pharmacy claims data, patient self-reports of adher-
ence, and electronic dose-monitoring devices have reported
that 14% to 90% of patients do not use their drops as pre-
scribed.89–94 In line with this, although the topical PGAs
are once-daily medications, a pharmacy claims-based study
showed that on average, patients filled their PGA pre-
scription and had medication available for dosing only
37% of the days in a year.90 The problem is compounded
by the difficulty many patients have in instilling their eye
drops,95 and the most commonly reported reasons for pa-
tients not using their eye drops as prescribed include for-
getfulness, inconvenience because of the dosing frequency,
lack of understanding of the disease, medication cost, and
difficulty in eye drop administration.91,93,95,96 Patient non-
adherence to glaucoma medications is a significant clinical
concern, because evidence suggests that adherence to the pre-
scribed medication is needed for optimal visual outcomes.92,97
A biodegradable sustained-release bimatoprost implant
(Bimatoprost SR) has been developed to address the prob-
lem of nonadherence in glaucoma and lower IOP without
need for daily eye drops. Bimatoprost SR was manufactured
FIG. 7. Dose-dependent effects of bimatoprost acid on levels of mRNA for MMPs and TIMPs in human nonpigmented
ciliary epithelial cells. Cultures were exposed to 10, 100, or 1,000 mM bimatoprost acid (B) for 24 h or to no drug (control,
C), and mRNA levels were quantified by quantitative polymerase chain reaction. *P < 0.05, **P < 0.01, ***P < 0.001 vs.
control. Adapted from Yamada et al.87 under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/). The superimposed black and red arrows show for comparison the maximal
iris-ciliary body bimatoprost plus bimatoprost acid concentrations obtained after topical bimatoprost treatment and Bi-
matoprost SR administration, respectively, in a drug distribution study in beagle dogs.102 Bimatoprost SR, bimatoprost
sustained-release implant; TIMP, tissue inhibitor of metalloproteinase.
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on the Novadur (Allergan plc, Dublin, Ireland) platform for
drug delivery, which uses biodegradable polymers similar to
those in biodegradable sutures and has demonstrated a long
track record of safety with intraocular use.98 The implant
consists of bimatoprost embedded in a polymer matrix for-
mulated to provide nonpulsatile, consistent drug release over
time (ie, zero-order kinetics). The implant was designed to
be administered intracamerally and to slowly release bi-
matoprost to lower IOP for 4–6 months. A single-use, 28-
gauge proprietary applicator (Fig. 8) is used to place the
implant into the anterior chamber of the eye in an office
procedure. After administration, bimatoprost is slowly re-
leased as the matrix is hydrolyzed and metabolized to car-
bon dioxide and water.
The concentration of bimatoprost achieved in outflow tissues
was an important consideration in the formulation of an implant
with potential to provide sustained IOP lowering. It is well un-
derstood that the effects of topical PGA treatment on IOP last for
several weeks after stopping use of PGA eye drops. In fact, a
washout period of 4 weeks for PGAs has typically been used in
clinical trials in glaucoma, and there is evidence of lingering
effects of the PGAs in some patients beyond 4 weeks.99 We
hypothesize that the continued IOP-lowering effect seen in some
patients for several weeks after topical PGA washout reflects the
time required for reversal of the PGA-induced MMP-mediated
remodeling of outflow tissues. Because the effects of PGAs on
MMP expression are concentration dependent, we reasoned that
it might be possible to achieve more extensive tissue remodeling,
and a longer remnant effect on IOP, if a higher drug concentra-
tion was achieved in the outflow tissues. The drug content of the
10-mg Bimatoprost SR that was developed is similar to that of a
single drop of topical bimatoprost 0.03% ophthalmic solution,100
but the implant can achieve higher bimatoprost concentrations in
outflow tissues because it takes advantage of an intracameral
route for drug delivery. Thus, >80% of drug is delivered to
outflow tissues, whereas <5% of drug reaches intraocular tissues
after topical administration of an eye drop.101,102
The ability of Bimatoprost SR to provide targeted deliv-
ery of high bimatoprost concentrations to ocular outflow
tissues was demonstrated in a drug distribution study using
normotensive beagle dogs.102 The time course of ocular
drug concentrations after implant administration was con-
sistent with the kinetics of drug release from the implant
in vitro, where drug release is complete in less than 3
months: in the dog study, the implants had released 99.8%
of their drug load and ocular tissue drug levels had signifi-
cantly declined by 80 days after intracameral administra-
tion.102 Drug levels in ocular surface and periocular tissues
such as the conjunctiva, eyelids, and periorbital fat were
markedly reduced or undetectable after Bimatoprost SR
15 mg administration compared with 7 days of topical dosing
with bimatoprost 0.03% (Fig. 9), suggesting the potential for
reduced PGA side effects, such as conjunctival hyperemia
and periorbitopathy, with the implant. In contrast, and im-
portantly, the iris-ciliary body maximal drug concentration,
measured 52 days postdose, was 4,400-fold higher after
Bimatoprost SR 15mg administration than after 7 days of
topical bimatoprost 0.03% administration, and drug levels in
the aqueous humor, a proxy target because of its close
proximity to the TM and ciliary body, were *10-fold
higher after Bimatoprost SR administration compared with
topical dosing (Fig. 9). The high drug concentrations
achieved in outflow tissues with the implant were not as-
sociated with any drug-related toxicities.102
It is of interest that twice-daily topical dosing of either
latanoprost103 or bimatoprost104 results in decreased IOP-
FIG. 8. Bimatoprost SR is a first-in-class, sustained-
release, bimatoprost implant that is administered in-
tracamerally. (A) Photograph of an implant (10-mg dose
strength; arrow) superimposed on an image of a dime. The
implant is similar in size to the ‘‘i’’ in Liberty on the dime;
the shape is cylindrical (radius*200mm, length*1.1 mm).
(B) Photograph of a single-use, 28-gauge applicator used for
implant administration.
FIG. 9. Mean maximal drug concentrations for bimatoprost
plus bimatoprost acid in ocular tissues associated with PGA-
related adverse effects (A) and associated with IOP lowering
(B) after administration of either Bimatoprost SR 15mg or
topical bimatoprost 0.03% once daily for 7 days in beagle
dogs. Republished from Seal et al.,102 under the terms of the
Creative Commons License (http://creativecommons.org/
licenses/by/4.0). n= 2 animals/4 eyes per time point. BLQ,
below the limit of quantitation; Cmax, maximal observed
concentration; PGA, prostaglandin analog/prostamide.
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lowering efficacy compared with once-daily dosing. In con-
trast, nonclinical105,106 and clinical100 studies with Bimato-
prost SR have not shown diminished IOP-lowering effects
with higher drug release rates from the implant. A possible
explanation is that the intraocular drug levels achieved with
intracameral delivery,102 and the subsequent MMP upregu-
lation in target tissues, far exceed that achieved with topical
dosing, and this may overcome the ceiling effect on IOP
reduction that is observed with topical dosing. Alternatively,
other mechanisms of IOP lowering may be unlocked with
intracameral delivery, such as reduction of the episcleral
venous pressure, which has been observed with a PGA only
with intracameral dosing107 and not with topical dosing108 in
nonclinical studies. Sustained delivery of bimatoprost to
conventional outflow tissues could potentially alter the pro-
portion of high to low flow regions because of increased
MMP activation,109,110 thus increasing total outflow facility.
During the first clinical trial of Bimatoprost SR, the phase
1/2 APOLLO study,100,111 the formulation was modified to
optimize the rate of biodegradation and drug release, and 6-,
10-, 15-, and 20-mg dose strengths of a second-generation
implant were tested in 75 patients with open-angle glaucoma
in the study eye. In APOLLO, patients received 1 or at most
2 administrations of implant and were followed for 2 years.
The implant provided dose-dependent IOP lowering over
the first 16 weeks, with IOP-lowering efficacy similar to
that of a topical PGA.100 Remarkably, 28% of the Bima-
toprost SR-treated eyes were controlled without use of any
additional treatment (rescue topical medication or implant
retreatment) up to 24 months after a single implant ad-
ministration111 (Fig. 10). Because the implants contain a
relatively small amount of drug (low mg), and results from
nonclinical pharmacokinetics studies show nondetectable
intraocular drug levels at 4.5 months after administration
(Allergan, data on file, 2019), this sustained IOP lowering
is unlikely to be accounted for by continued drug presence.
Furthermore, in preclinical toxicology studies, there were
no signs of uveitis or histologic evidence of inflammation
that could be associated with a reduction of IOP (Allergan,
data on file, 2015). Although residual implant depleted of
drug may remain in the iridocorneal angle for weeks or
months before being completely biodegraded, some of the
patients who had IOP controlled up to 24 months after a
single implant had no residual implant visible on gonio-
scopy at month 24 (Fig. 11).
The 10- and 15-mg dose strengths of Bimatoprost SR were
advanced in development into phase 3 evaluation, and 2
double-masked, prospective, 20-month phase 3 studies with
identical protocols (ARTEMIS 1 and 2; NCT02247804 and
NCT02250651) were designed to evaluate the efficacy and
safety of 3 administrations of these dose strengths of im-
plant at 4-month intervals compared with twice-daily topical
timolol 0.5% in a total of 1,122 patients with open-angle
glaucoma or ocular hypertension. The ARTEMIS 1 study
was recently completed; the ARTEMIS 2 study is ongoing.
The primary database lock for each study occurred when the
last enrolled patient completed the Week 12 visit, and all
available data from the pooled dataset were analyzed. Both
dose strengths of Bimatoprost SR met the primary end point
of noninferiority to topical timolol in IOP lowering through
Week 12 (Craven, et al. American Academy of Ophthal-
mology 2019 Annual Meeting, October 12–15, 2019, San
Francisco, CA). Furthermore, after receiving 3 implants over
8 months, many patients had sustained IOP lowering for the
remainder of the 20-month study. In the analysis of the
pooled study data from the primary database lock, patients
treated with Bimatoprost SR 10mg had an 80% estimated
FIG. 10. Percentage of study eyes that remained in the
study with no additional IOP-lowering treatment (topical
medication or laser/surgery) after a single administration of
Bimatoprost SR in the phase 1/2 APOLLO study. Adapted
from Craven et al.,111 under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/).
FIG. 11. Gonioscopic photographs and IOP in a represen-
tative patient with open-angle glaucoma who demonstrated
sustained IOP lowering after a single administration of
Bimatoprost SR 6 mg on Day 1 in the APOLLO study. The
baseline IOP was 24.5 mm Hg. (A) At Week 2, the implant
was visible in the iridocorneal angle. (B) At Month 24, no
residual implant was visible on gonioscopy, yet the IOP re-
mained well controlled at 15.5 mm Hg. Reproduced by per-
mission of E. Randy Craven, Biodegradation of Intracameral
Bimatoprost Sustained-Release Implant (Bimatoprost SR) in
a 24-Month, Phase 1/2 Study in Glaucoma Patients. Presented
at the American Society of Cataract and Refractive Surgery
2019 Annual Meeting, May 3–7, 2019, San Diego, CA.
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probability of not using any additional IOP-lowering treat-
ment (topical medication or laser/surgical procedure) for
1 year after the third administration.
These phase 3 study results showing long-term, sustained
IOP lowering with Bimatoprost SR are consistent with the
phase 1/2 study results, in which the estimated probability of
receiving no additional treatment for 2 years after a single
Bimatoprost SR 10 or 15 mg administration was 36%. We
propose that the most reasonable explanation for these findings
is that the high bimatoprost concentrations in target tissues
after Bimatoprost SR administration alter the MMP/TIMP
balance in a manner that favors more durable tissue re-
modeling of outflow pathways, resulting in sustained IOP
lowering in the absence of continued drug exposure.
We hypothesize that the high drug levels produced in
target tissues by the implant result in enhanced upregulation
of MMPs, leading to more extensive loss of ECM in both
the ciliary body and TM, as illustrated in Fig. 12. The time it
takes to reverse these changes, and for the tissues to nor-
malize, equates to the duration of IOP reduction that occurs
beyond drug presence. Additional laboratory work is in
progress to evaluate the differential effects of various con-
centrations of PGAs on the histology of the anterior segment
to test this hypothesis.
The long-term clinical effects of this disease-modifying
approach for treating glaucoma are currently being investi-
gated in a 2-year extension study of the phase 3 clinical trials
(ClinicalTrials.gov Identifier: NCT03891446). In the exten-
sion study, patients completing the ARTEMIS 1 and 2 studies
or 2 other phase 3 studies comparing Bimatoprost SR to se-
lective laser trabeculoplasty (NCT02250651, NCT02636946),
who have not received any additional IOP-lowering medica-
tion at the original study completion, will continue follow-up
to evaluate the duration of IOP lowering without requiring
additional treatment.
Conclusion
MMPs are ubiquitous in the body and have essential roles
in both normal physiology and pathology. In the eye, both
MMPs and the MMP/TIMP ratio in ocular tissues involved in
aqueous humor outflow have an important role in the regulation
of IOP. Treatment of glaucoma patients with topical PGAs
increases MMP activity and ECM turnover in aqueous outflow
tissues, resulting in enhanced aqueous outflow through con-
ventional and unconventional routes and reduced IOP. By
exposing tissues to high concentrations of PGA with an in-
tracameral implant, the mechanism of IOP lowering through
FIG. 12. Proposed mechanism for the extended duration of effect of the bimatoprost implant. (Left) The mechanism of
IOP lowering with topical PGAs involves remodeling of outflow pathways, seen here in the monkey ciliary body after 1 year
of topical bimatoprost treatment (top) and in the monkey TM after 1 year of topical latanoprost treatment (bottom). (Right)
Artist’s rendition of the hypothesized mechanism for sustained IOP lowering with the implant. The high tissue concen-
trations of bimatoprost after implant administration are proposed to result in higher expression of MMPs and a shift in the
MMP/TIMP balance favoring reduction in the ECM and more durable tissue remodeling, resulting in a sustained increase in
aqueous outflow and a longer duration of IOP reduction. Images on left are used with permission of ARVO, from
Morphological Changes in the Anterior Eye Segment after Long-Term Treatment with Different Receptor Selective
Prostaglandin Agonists and a Prostamide, Richter et al.76; permission conveyed through Copyright Clearance Center, Inc.,
Arrows indicate increased areas with empty space because of ECM degradation. Scale bar: (top) 50 mm; (bottom) 20 mm.
CM, ciliary body; JCT, juxtacanalicular tissue.
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MMP activation can be exploited to cause durable IOP re-
duction, presumably because the high drug concentrations
produce greater tissue remodeling compared with the lower
drug levels achieved with eye drops. The magnitude of the
remodeling may be influenced by factors including the dose,
the PGA, and the duration of drug exposure.
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